近日，一名原央视主持人在直播间哭诉自己11岁的女儿患上"正食症"的新闻引起了广泛关注。据称，其 女儿由于痴迷"纯净"饮食，完全戒掉了油脂和碳水，只吃水煮菜，蛋白质也吃得非常少，以致免疫力下 降，患流感后心肌损伤，心率一度飙到120次/分钟，最终被确诊为"正食症"并住院治疗。 此事将"正食症"推进了公众视野。什么是"正食症"？为何对"健康饮食"的极致追求，反而导致了危害健 康的结果？"正食症"这种心理行为问题又为何偏偏容易盯上青少年？ "正食症"的真相 在某百科上，"正食症"被解释为一种对健康饮食过度执着的进食障碍，表现为极端限制食物种类、追 求"纯净"饮食，最终导致严重营养不良和脏器损伤。它并非真正的健康饮食行为，而是一种需要干预的 心理疾病。 然而，在医学的严谨框架内，"正食症"却并非一个独立的诊断标签。 林溪的治疗初期异常艰难。面对要求增加进食的医疗方案，她内心抗拒，但在医生的监管下，她最终还 是被动配合了。随着体重逐步恢复，她的精神状态开始改善，认知功能也从营养不良的"迷雾"中逐渐清 晰。 林溪的医生解释说，在严重营养不良状态下，大脑功能会受损，患者往往无法理性认识到自己行为的病 态。当身体得到修复，大 ...

以下文章来源于故事FM ，作者收集故事的人 故事FM . 用你的声音，讲述你的故事。 本文来自微信公众号： 故事FM ，讲述者：章章、小图、子晨，主播：爱哲，制作人、文案整理： 金松，原文标题：《被"白幼瘦"绑架的青春：为减肥患上进食障碍的女孩，现在怎么样了？ | 故事 FM》，题图来自：AI生成 今年，北京大学一项覆盖了全国 4 万多名青少年的进食障碍流行病学调查显示， 中国有超过五分之 一 （21.18%） 的青少年存在疑似进食障碍风险。 什么是进食障碍 （ED， Eating Disorders） ？通俗来讲，这是一种精神类疾病，患者通常过分关注 自己的体重、体型以及食物，并因此出现进食行为异常， 厌食、暴食或者贪食 的情况。 尤其是其中的 神经性厌食症，它是所有精神疾病中死亡率最高的一种， 死亡率高达 10%。患者可能 因极度营养不良导致多器官衰竭而死亡。 令人不安的是，进食障碍患者年龄有 明显的低龄化趋势 。到 2022 年，18 岁以下的未成年人，在所 有就诊的神经性厌食患者中占比高达 77.6%。 为什么减着减着，就减出病了？这病是如何演化的？能严重到什么程度？又怎么治？今天我们找到了 3 位经 ...

Group 1 - The core finding from the real-world study presented by Novo Nordisk at the EASD conference indicates that 46% of patients using semaglutide (brand name: Ozempic) reported a significant reduction in "food noise," which refers to uncontrollable thoughts about food [2] - Semaglutide, a GLP-1 drug, works by suppressing appetite, slowing gastric emptying, and inducing a feeling of fullness, thereby aiding weight loss [2] - Novo Nordisk's recent data shows that 84.5% of weight loss in patients was derived from body fat, preserving muscle function, which is crucial for maintaining overall health during weight loss [3] Group 2 - Novo Nordisk is actively addressing competition from Eli Lilly and has recently announced a large-scale global layoff, resulting in an over 11% increase in its stock price within a week [3] - The company aims to enhance decision-making efficiency and accelerate clinical pipeline progress, as stated by its Chief Scientific Officer Martin Holst Lange [3] - Novo Nordisk is exploring treatments for various obesity-related complications and is validating the efficacy of its weight loss drug for Alzheimer's disease, with expectations to obtain clinical data by the end of 2025 [3] - Positive clinical trial results for the Alzheimer's study could potentially generate up to $15 billion in additional annual revenue for Novo Nordisk, according to UBS analysis [3]

Core Insights - Novo Nordisk presented real-world research results on the use of semaglutide for weight loss at the EASD annual meeting, indicating that 46% of patients reported a significant reduction in "food noise" after treatment [1][3] - The company reported that 84.5% of weight loss from semaglutide comes from body fat, preserving muscle function, which is crucial for overweight or obese patients [3] - Novo Nordisk is facing competition from Eli Lilly and has recently announced significant layoffs, resulting in an over 11% increase in stock price within a week [3] - The company is exploring treatments for various obesity-related conditions and is validating the efficacy of its weight loss drug for Alzheimer's disease, with potential annual revenue of up to $15 billion if clinical trials succeed [4] Company Developments - Novo Nordisk aims to enhance decision-making efficiency and accelerate clinical pipeline progress following recent layoffs [3] - The company is developing therapies targeting a range of conditions associated with obesity, including arthritis and sleep apnea [4] - The ongoing large-scale clinical study for Alzheimer's disease is the first of its kind for GLP-1 drugs, with results expected by the end of 2025 [4]

Core Viewpoint - The article discusses the increasing prevalence of eating disorders, particularly among adolescents and young adults, highlighting the psychological and societal factors contributing to these conditions [8][71][72]. Group 1: Overview of Eating Disorders - Eating disorders are characterized by abnormal eating behaviors and excessive concern about food, weight, and body shape, often linked to psychological factors [8]. - The World Health Organization reports that eating disorders are most common among adolescent and young adult females and have the highest mortality rate among psychiatric disorders [8][71]. Group 2: Rising Trends and Statistics - Data from mental health institutions indicate a yearly increase in the prevalence of eating disorders in China, with a significant rise in cases among minors [9][71]. - In 2017, the Shanghai Mental Health Center reported 1,599 outpatient cases of eating disorders, which increased to 4,281 by 2021, showing a trend towards younger patients [71]. Group 3: Psychological Factors and Triggers - Factors such as academic pressure, social media influence, and family comments about body image contribute to the development of eating disorders [14][15][18][20]. - The peak age for the onset of anorexia and bulimia is between 15 and 25 years, with significant life transitions, such as moving from middle school to high school, being critical periods [12][13]. Group 4: Personal Experiences and Recovery - Personal narratives illustrate the struggle with eating disorders, emphasizing the internal conflict between the desire for control and the reality of losing control [32][34][75]. - Recovery from eating disorders is described as a gradual process involving physical, psychological, and social dimensions, with a focus on finding balance rather than complete eradication of the disorder [73][76]. Group 5: Community Support and Awareness - Initiatives like ED Healer aim to provide peer support and raise awareness about eating disorders through workshops, lectures, and art exhibitions [69][70]. - The article highlights the importance of community and social support in the recovery process, as well as the need for better mental health education [69][68].